Tamoxifen in Treating Women With High-Risk Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
NCIC Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00002542
First received: November 1, 1999
Last updated: January 18, 2011
Last verified: January 2011
  Purpose

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase III trial to study the effectiveness of tamoxifen following surgery and chemotherapy in treating women who have stage I breast cancer at high risk of recurrence or stage II or stage III breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: CMF regimen
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: epirubicin hydrochloride
Drug: fluorouracil
Drug: methotrexate
Drug: tamoxifen citrate
Radiation: radiation therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: DOUBLE-BLIND RANDOMIZED TRIAL OF TAMOXIFEN VERSUS PLACEBO IN PATIENTS WITH NODE POSITIVE BREAST CANCER WHO HAVE COMPLETED CMF, CEF OR AC ADJUVANT CHEMOTHERAPY

Resource links provided by NLM:


Further study details as provided by NCIC Clinical Trials Group:

Estimated Enrollment: 800
Study Start Date: July 1993
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES: I. Compare the duration of overall survival and disease-free survival in premenopausal women with operable, high risk node negative or axillary node-positive breast cancer who have undergone complete surgical resection of all known disease by means of total or partial mastectomy, and have received standard adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF), cyclophosphamide, epirubicin, and fluorouracil (CEF), or doxorubicin and cyclophosphamide (AC) followed by either daily tamoxifen for 5 years or placebo. II. Compare the short- and long-term toxicity in patients receiving tamoxifen versus placebo. III. Monitor follicle-stimulating hormone, luteinizing hormone, and estradiol levels, and determine whether overall survival and disease-free survival are affected by hormonal or menopausal status during or at completion of adjuvant chemotherapy or during or after tamoxifen or placebo treatment in these patients.

OUTLINE: This is a randomized, double blind study. Patients are stratified by adjuvant chemotherapy regimen (cyclophosphamide, epirubicin, and fluorouracil vs cyclophosphamide, methotrexate, and fluorouracil vs cyclophosphamide and doxorubicin), hormone receptor status (ER and/or PR positive vs ER and PR negative), number of positive nodes (1-3 vs 4-9 vs 10 or more), and participating institution. Patients receive one of three regimens of adjuvant chemotherapy at the discretion of the investigator. Regimen A: Patients receive oral cyclophosphamide on days 1-14 and epirubicin IV and fluorouracil IV on days 1 and 8. Courses repeat every 28 days for a total of 6 courses. Following chemotherapy, lumpectomy patients receive local radiotherapy daily for 5 weeks. Regimen B: Patients receive oral cyclophosphamide on days 1-14 or cyclophosphamide IV on day 1 and 8, methotrexate on days 1 and 8, and fluorouracil IV on days 1 and 8. Courses repeat every 28 days for a total of 6 courses. Concurrent with or following chemotherapy, lumpectomy patients receive local radiotherapy daily for 5 weeks. Regimen C: Patients receive doxorubicin IV and cyclophosphamide IV every 21 days for a total of 4 courses. Following chemotherapy, lumpectomy patients receive local radiotherapy daily for 5 weeks. Patients are then randomized to receive either oral tamoxifen or a placebo once daily for 5 years, beginning within 6 weeks of completion of chemotherapy. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for survival.

PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study over 4 years.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS: Adenocarcinoma of the breast with 1 or more histologically proven positive axillary nodes OR Adenocarcinoma of the breast with negative axillary nodes or adverse prognostic factors such that the patient is at high risk for recurrence and node negative lesion is characterized by the following features: Tumor at least 1 cm Poorly differentiated, SBR grade III, or MSBR grade V and/or lymphatic/vascular invasion Pathologic review by experienced breast pathologist recommended if grade is unspecified and lymphatic/vascular invasion is absent Disease considered potentially curable and treated by 1 of the following: Complete surgical removal of the breast plus axillary node dissection Partial surgical removal of the breast plus axillary node dissection, with the intention of giving breast irradiation following completion of an adjuvant chemotherapy regimen Regional nodal or chest wall irradiation not prohibited but strongly discouraged No evidence of residual tumor in the axilla following dissection No microscopic evidence of residual tumor at the resection margins following total mastectomy Further excision highly recommended if there is microscopic residual disease present at partial mastectomy margins If further excision is not undertaken, a radiotherapy boost to the tumor bed is required in addition to breast irradiation given following protocol chemotherapy Disease clinically staged prior to surgery as T1-T3a, N0-2, M0 No clinical T4 disease, i.e.: No extension to the chest wall No edema (including peau d'orange) No skin ulceration No satellite skin nodules confined to the same breast No inflammatory carcinoma Disease pathologically staged following surgery as TNM stage I, II, or III (T0-4; N0-2; M0) T4 allowed only with dermal involvement on pathology assessment No evidence of metastatic disease beyond the homolateral axillary nodes on pre-chemotherapy chest x-ray, bone scan (with radiographs of suspicious areas), and abdominal ultrasound (required only if bilirubin, alkaline phosphatase, or AST/ALT are elevated) Simultaneous bilateral breast carcinoma allowed Complete tumor resection on both breasts required Axillary dissection on both sides must meet criteria as above if both sides are clinically node-positive Axillary dissection on the second side optional if the axilla is clinically negative at the time of surgery and the other side is node-positive Adjuvant chemotherapy must begin within 14 weeks of initial pathologic diagnosis Hormone receptor status: Any receptor level allowed (values must be available if biochemical method used; immunocytochemical assay permitted)

PATIENT CHARACTERISTICS: Age: Not specified Sex: Female Menopausal status: Pre- or perimenopausal, i.e., meeting at least 1 of the following criteria: Normal menstruation Amenorrhea for less than 1 year (up to 3 years in patients under age 52) Biochemical evidence of ovarian function Hysterectomy without bilateral oophorectomy in patients under age 56 Premenopausal women no greater than age 50 who were started on replacement hormone therapy before amenorrhea are eligible Performance status: ECOG 0-2 prior to chemotherapy Hematopoietic: WBC at least 3,000/mm3 Polymorphs and bands at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: (unless abdominal ultrasound indicates liver metastasis) Alkaline phosphatase no greater than 2 times normal AST and/or ALT no greater than 2 times normal Renal: Not specified Other: No history of serious underlying medical illness or psychiatric or addictive disorder No second malignancy within 5 years except: Curatively treated nonmelanomatous skin cancer Curatively treated endometrium, colon, or thyroid cancer or carcinoma in situ of the cervix No plan for pregnancy during the 5-year study period Fertile women must use effective contraception (other than oral contraception) Accessible for treatment and follow-up

PRIOR CONCURRENT THERAPY: Biologic therapy: Colony-stimulating factors allowed (use must be documented) Chemotherapy: No prior chemotherapy No concurrent other cytotoxic therapy Endocrine therapy: Adjuvant tamoxifen (20 mg po daily) allowed up to 2 weeks before or during adjuvant chemotherapy provided drug is discontinued at randomization No long-term prednisone or other hormones Radiotherapy: See Disease Characteristics Surgery: See Disease Characteristics

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002542

  Hide Study Locations
Locations
Canada, Newfoundland and Labrador
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada, AIB 3V6
Canada
The Royal Victoria Hospital
Barrie, Canada, L4M 6M2
William Osler Health Centre, Brampton Memorial
Brampton, Canada, L6R 3J7
Tom Baker Cancer Centre
Calgary, Canada, T2N 4N2
PEI Cancer Treatment Centre,Queen Elizabeth Hospital
Charlottetown, Canada, C1A 8T5
Cross Cancer Institute
Edmonton, Canada, T6G 1Z2
QEII Health Sciences Center
Halifax, Canada, B3H 1V7
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Canada, L8V 5C2
Centre Hospitalier Regional de Lanaudiere
Joliette, Canada, J6E 6J2
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Canada, K7L 5P9
L'Hotel-Dieu de Levis
Levis, Canada, G6V 3Z1
London Regional Cancer Program
London, Canada, N6A 4L6
Credit Valley Hospital
Mississauga, Canada, L5M 2N1
CHUM - Pavillon Saint-Luc
Montreal, Canada, H3X 3J4
CHUM - Hopital Notre-Dame
Montreal, Canada, H2L 4M1
McGill University - Dept. Oncology
Montreal, Canada, H2W 1S6
CHUM - Hotel Dieu du Montreal
Montreal, Canada, H2W 1T8
Stronach Regional Health Centre at Southlake
Newmarket, Canada, L3Y 2P9
Lakeridge Health Oshawa
Oshawa, Canada, L1G 2B9
Ottawa Health Research Institute - General Division
Ottawa, Canada, K1H 8L6
Penticton Regional Hospital
Penticton, Canada, V2A 3G6
Peterborough Regional Health Centre
Peterborough, Canada, K9H 7B6
University Institute of Cardiology and
Quebec, Canada, G1V 4G5
CHUQ-Pavillon Hotel-Dieu de Quebec
Quebec City, Canada, G1R 2J6
CHA-Hopital Du St-Sacrement
Quebec City, Canada, G1S 4L8
Allan Blair Cancer Centre
Regina, Canada, S4T 7T1
Atlantic Health Sciences Corporation
Saint John, Canada, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Canada, S7N 4H4
Algoma District Cancer Program
Sault Ste. Marie, Canada, P6A 2C4
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Canada, J1H 5N4
Niagara Health System
St. Catharines, Canada, L2R 7C6
Regional Cancer Program of the Hopital Regional
Sudbury, Canada, P3E 5J1
BCCA - Fraser Valley Cancer Centre
Surrey, Canada, V3V 1Z2
Thunder Bay Regional Health Science Centre
Thunder Bay, Canada, P7B 6V4
Mount Sinai Hospital
Toronto, Canada, M5G 1X5
Humber River Regional Hospital
Toronto, Canada, M9N 1N8
St. Joseph's Health Centre
Toronto, Canada, M6R 1B5
St. Michael's Hospital
Toronto, Canada, M5B 1W8
Toronto East General Hospital
Toronto, Canada, M4C 3E7
Odette Cancer Centre
Toronto, Canada, M4N 3M5
Trillium Health Centre - West Toronto
Toronto, Canada, M9C 1A5
Univ. Health Network-Princess Margaret Hospital
Toronto, Canada, M5G 2M9
Univ. Health Network-The Toronto General Hospital
Toronto, Canada, M5G 2C4
Women's College Hospital
Toronto, Canada, M5S 1B2
BCCA - Vancouver Cancer Centre
Vancouver, Canada, V5Z 4E6
BCCA - Vancouver Island Cancer Centre
Victoria, Canada, V8R 6V5
Windsor Regional Cancer Centre
Windsor, Canada, N8W 2X3
CancerCare Manitoba
Winnipeg, Canada, R3E 0V9
Sponsors and Collaborators
NCIC Clinical Trials Group
Investigators
Study Chair: Vivien H.C. Bramwell, MB, BS, PhD, FRCP London Regional Cancer Program at London Health Sciences Centre
  More Information

Additional Information:
Publications:
Bramwell VHC, Pritchard KI, Tu D, et al.: How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). [Abstract] Breast Cancer Res Treat 106 (1): A-3055, 2007.
Bramwell VH, Pritchard KI, Tu D, et al.: Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): interim results of NCIC-CTG MA.12. [Abstract] J Clin Oncol 25 (Suppl 18): A-547, 2007.

Responsible Party: Ralph Meyer, M.D, NCIC Clinical Trials Group
ClinicalTrials.gov Identifier: NCT00002542     History of Changes
Other Study ID Numbers: MA12, CAN-NCIC-MA12, NCI-V93-0323, CDR0000063224
Study First Received: November 1, 1999
Last Updated: January 18, 2011
Health Authority: United States: Federal Government

Keywords provided by NCIC Clinical Trials Group:
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Cyclophosphamide
Methotrexate
Fluorouracil
Liposomal doxorubicin
Doxorubicin
Tamoxifen
Epirubicin
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Antimetabolites
Dermatologic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on October 01, 2014